IGM Biosciences Inc. [IGMS] Chief Commercial Officer makes an insider sale of 936 shares worth $8818.0.


IGM Biosciences Inc.’s recent filing unveils that its Chief Commercial Officer Gauthier George unloaded Company’s shares for reported $8818.0 on Jul 03. In the deal valued at $9.42 per share,936 shares were sold. As a result of this transaction, Gauthier George now holds 40,017 shares worth roughly $ 0.28 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Topsoe Jakob Haldor bought 3,500 shares, generating $32,375 in total proceeds. Upon buying the shares at $9.25, the Director now owns 81,644 shares.

Before that, Topsoe Christina Teng bought 3,000 shares. IGM Biosciences Inc. shares valued at $27,957 were divested by the Director at a price of $9.32 per share. As a result of the transaction, Topsoe Christina Teng now holds 9,800 shares, worth roughly $68306.0.

PT values the company’s stock at a premium of 87.33 to its Friday closing price.

Price Performance Review of IGMS

On Friday, IGM Biosciences Inc. [NASDAQ:IGMS] saw its stock fall -2.52% to $6.97. On the same session, the stock had its day’s lowest price of $6.93, but rose to a high of $7.46. Over the last five days, the stock has lost -6.44%. IGM Biosciences Inc. shares have fallen nearly -59.02% since the year began. Nevertheless, the stocks have fallen -64.09% over the past one year. While a 52-week high of $28.20 was reached on 01/17/23, a 52-week low of $7.03 was recorded on 09/01/23. SMA at 50 days reached $8.98, while 200 days put it at $15.03. A total of 0.21 million shares were traded, compared to the trading of 0.15 million shares in the previous session.

Levels Of Support And Resistance For IGMS Stock

The 24-hour chart illustrates a support level at 6.78, which if violated will result in even more drops to 6.59. On the upside, there is a resistance level at 7.31. A further resistance level may holdings at 7.65. The Relative Strength Index (RSI) on the 14-day chart is 31.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.41, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.16%. Stochastics %K at 11.06% indicates the stock is a buying.

How much short interest is there in IGM Biosciences Inc.?

A steep rise in short interest was recorded in IGM Biosciences Inc. stocks on Aug 14, 2023, growing by 0.52 million shares to a total of 5.48 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 4.96 million shares. There was a rise of 9.49%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 36.16% of the overall stock float, the days-to-cover ratio (short ratio) rose to 26.43.

IGM Biosciences Inc. [IGMS] – Who Are The Largest Shareholders?

In filings from Baker Bros. Advisors LP, it is revealed that the company now owns 3,157,210 shares, or roughly 10.15% of the outstanding IGMS shares. In other words, the investor’s shares have risen by 554 from its previous 13-F filing of 3156656.0. Additionally, T. Rowe Price Associates, Inc. increased 54.94% of its stake after which the total value it holdings stand at $33,276,674, while Redmile Group LLC reduced -10.88% of its stake to hold $31.62 million in the firm. Over the last quarter, Invus Public Equities Advisors LL purchased 12,272 shares of IGM Biosciences Inc., while Fidelity Management & Research Co bought 1,290,528 shares. At present, Millennium Management LLC is holding 984,663 shares valued at $10.48 million. RA Capital Management LP owned 937,500 shares of the company at the time of its most recent 13F filing, worth $9.97 million.

According to FactSet, IGM Biosciences Inc.’s share price will average $21.80 in the next year, based on opinions of analysts polled by the firm. This is up nearly 151.75 percent from its previous closing price of $7.15. Analysts expect IGM Biosciences Inc. stock to reach the higher price of $48.00, while the lowest price estimate is $11.00. However, 10 analysts have rated IGMS stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here